Detroit Free Press from Detroit, Michigan • Page 31

Insida this section Wednesday, Apiil 9, 1S20 MAGAZINES 0 no mm rff 1" SYLVIA PORTER 7 CLASSIFIED 10-14 FEATURE PAGE 15 DETROIT FREE PRESS psgos 6-10 i A 1 I ivrei few" 4- jS '-Wij'WiOW Free Press Illustration by DOMINIC TRUPIANO Money meets music: Stock broker Carol Payne, far right, consults with members of Prismatic, a jazz-rock group she manages. They are, from left. Penny Kuypers, Kuypers and Michael Colone. i rfflsssH 4' ---'-SA i tr tiiiiinii n.i iri-Tnii Ti.inim.niii.i-ir,-,i- gjfci L-. T-thiWI i mwiwui Free Press Photo by PATRICIA BECK ock and stocks harmonize for Payne 'This is a gutsy, high pressure business By LAURA BERMAN Free Press Staff Writer The hierarchy of Women in Finance, a 100-member group founded three years ago by Carol Ann Payne, will tell you something about the character of its founder.

Payne is neither president nor director. Her title is chairman of the board She presides over a "hand-picked" board of directors. Ordinarily, groups with voluntary membership, particularly feminist ones like Women in Finance, embrace democracy as a principle. But Carol Payne does not expend her considerable energy on principles. Last fall, there were some stirrings in the group, talk of holding an election.

"Election?" responded Payne. "There will be no election." It's her group and she hasn't poured her energy and time into it to listen to others direct the show. "I said if there was going to be an election, I would just start another group." Carol Payne is, as she puts it, "a special case." She is 33, looks younger, earns an income in six figures and talks like Barbra Streisand playing Fanny Brice. In another era, she might have been the model for a high-powered career-girl heroine in a Howard Hawks screwball comedy she talks fast enough. PAYNE SELLS STOCKS during the day and manages a rock band in her spare time.

In other parts of her spare time, she is one of Helping Women" two stockbro- No promoters would back the group. Payne says she is. "They're my group and I'm committed to them," she says. And she has no intention of losing her money "Hell, no. Do I look like a dummy?" She doesn't.

She is a tall, slender woman, well-groomed in a knit suit, her hair cut short and pixie-ish, her manner self-confident and poised. The band members describe her as "an outlaw just like we are" and there is an element of truth to that. She Is no machine-stamped female executive out of the. pages of Mademoiselle or Savvy she has gotten where she is by force of will and brains, without an M.B.A. or any college degree, for that matter, and it hasn't been easy.

AT 19, SHE was newly arrived in Detroit from Boston. She was working in the trust department of a bank, married, attending college and pregnant. When, at 23, the marriage broke up, Payne worked first for a brokerage house as an investment counselor, then for a public relations firm as executive secretary. At 30, she was a secretary at a business machines company, stymied, she says, by the corporate system which wasn't sbout to budge for her. "I was just ahead of my time," she says now, staring at the cigarette in her hand contemplatively.

She had taken the job because she had a child and the hours were convenient but See PAYNE, Page 2C kers and an attorney who speak to women's groups about their careers; and the aforementioned chairman of the board of Women in Finance. Her goal is to "be running several businesses that will be managed by people I will handpick." She also would like to take "her band" Prismatic (band members, by the way, don't think of themselves as belonging to her) to Hollywood to receive a Grammy award. "You think I'm joking? I'm serious. When I say I'm going to do something, I do it," Payne says with some force, one finger raised in emphasis. She is not one to mince words nor to disguise her healthy ego with Payne, everything Is cards on the table and available for public inspection.

Not that she's guileless: she knows how to play politics, and she plays to win. She simply sees no need to hide the machinery. The Carol Payne method, for example: You set your goal, figure out what motions you have to go through to achieve it, you're very deliberate about it, keep your eyes on the goal, and surround yourself with people who can help you accomplish it." Her boss, Jacob Feldman, chairman of the board of First Heritage calls her "a dynamic lady. She helps a lot of la dles to learn they have to know how to manage their money. And she doesn't do it for her own glory." She calls her work for Women in Finance and Women Helping Women "part of the whole network thing." HER PREOCCUPATION days is the band, a six-member group that plays an idiosyncratic mix of jazz and rock, which she intends to launch to stardom.

'Most people in business play it very safe and smart," says Michael Colone, Prlsmatic's lead guitarist and songwriter. "But she has the extra vision that can see a little beyond, that takes an extra leap. I didn't trust her at first and I threw a lot of ideas at her. Instead of saying, 'No, you can't do she figured out how we could. She's making our dreams reality." The dream Colone is referring to is a concert.

Prismatic, which often plays as backup group at concerts, will hold a concert of its own at the Birmingham Theatre May 5. "I sat up at 1 2:30 one night with this brilliant idea," Carol Payne recalls modestly, sitting in her office at First Heritage Corp. in Southfield, "and 1 called Michael and said, 'I have this brilliant Idea. You're going to hold a IT ALTERED MY LIFE' Salk 5 years after vaccine Free Press Cartoon by JON BUECHEL If will be 25 yvars Saturday since the publir heard that Jonas Salk developed a vaccine against jHtlio. Now there is new interest in his vaccine in developing countries.

Will chicken burgers make diners squawk? Rsker's newest nroduct. which sold for trouble me as a student in medical school, when dogma held that you couldn't immunize with a killed virus, you had to go through an infection to get immunity. Later, the question became for me the basis of a serious intellectual challenge. Before the polio research, I worked with influenza viruses, helping to establish the efficacy of a killed-virus vaccine. The early polio vaccine technology needed much improvement, but the principle was proved.

I demonstrated that it could be 100 percent effective if the quantity of virus in the vaccine was sufficient." Now, Salk says, there is renewed interest in his killed- virus vaccine, particularly in developing countries. "The live-virus vaccine is highly effective In developed countries, even though the Introduction of live viruses still entails a degree of risk," he says. "But in the developing countries, where polio is on the increase, the drawback is that the live virus fails to establish the infection that leads to immunity because of intestinal inhibitors in the population. And so, at the present time, some European scientists are working with the kllied-vaccine principle in the developing countries, aiming at the goal of a one-dose preparation." AT THE INSTITUTE, a magnificent complex of laboratories and study units set on a bluff overlooking the Pacific, Salk holds the titles of founding director and resident fellow. His own laboratory group is concerned with the immunologic aspects of cancer and the mechanisms of autoimmune disease, such as multiple sclerosis, in which the immune system attacks the body's own tissues.

He also is writing and thinking about what might be called "biophilosophy," the application of a biological, evolutionary point of view to philosophical, cultural, social and psychological problems. "I think of biological knowledge as providing useful analogies for understanding human nature," says Salk, who has written two books, "Man's Unfolding" and "The Survival of the Wisest," explaining his biophilosophical approach "People think of biology in terms of such practical matters as drugs, but its contribution to knowledge about living systems and ourselves will In the future be equally important." See SALK, Pago 5C By GRACE GLUECK New York Times Shortly after the announcement that the Salk vaccine against poliomyelitis had proved a success, the late television personality Edward R. Murrow said to Dr. Jonas E. man, a great tragedy has befallen you you've lost your anonymity." The statement was in fact an understatement.

Saturday Is the 25th anniversary of the day, April 12, 1955, when the long-awaited tidings were made public that the vaccine developed by Salk was "safe, effective and potent" in extensive field' trials. The news set off a national celebration, and Salk became an instant hero. His research, begun in 1949 and financed by the March of Dimes campaign of the National Foundation for Infantile Paralysis, promised the demise of polio. The killed-virus vaccine he developed proved 80 to 90 percent effective, HONORS WERE heaped on the Manhattan-born scientist, among them a Congressional medal. Supporters, in particular the National Foundation, now called the March of Dimes Birth Defects Foundation, helped him build his dream of a research complex for the investigation of biological phenomena "from cell to society." It was called the Salk Institute for Biological Studies and opened in 1963 at La Jolla, Calif.

To the public, Salk is still a scientific superstar. But his success has not been free of controversy. Five years after the introduction of the Salk vaccine, the incidence of polio in this country had fallen 92 percent. Yet by 1 963, over the protests of Salk and the late Basil O'Connor, head of the foundation, uss of the Salk killed-virus vaccine a vaccine in which a virus is rendered inactive by chemical means although it is still able to stimulate the development of antibodies was supplanted by a live-virus oral vaccine developed by Albert B. Sabin.

The Sabin vaccine, which immunizes by establishing in the recipient's intestine a harmless infection that produces antibodies, was adopted for what was touted as its greater ease of administration and the supposedly superior immunity it conferred. Today it is the vaccine of choice in this country, although the Salk vaccine is available here and is used exclusively in the Scandinavian countries and the Netherlands. Not only did some of Salk's fellow scientists' take issue with his killed virus principle, they "3 By MARK D. FRANK United Press International After a steady diet of Big Macs and Whoppers, are Americans ready for chicken burgers made with deboned Leghorn fowl? The Cornell University food scientist who developed chicken hot dogs, chicken bologna and 37 other items thinks so. "It always takes a while to break down psychological barriers and to get people used to a new food product," said Prof.

Robert Baker of Ithaca, N.Y. "The one that had the worst barrier was chicken hot dogs. But now the younger generation doesn't have any hangups about them. "People will always eat hamburger but I think someday it (chicken burger) will be just as popular," said Baker, chairman of the department of poultry science in Cornell's state College of Agriculture and Life Sciences. BASED ON recent highly successful test marketing In the Ithaca area, Baker said he's certain his latest product frozen minced chicken has potential for widespread commercial production.

89 cents in one-pound packages, consists of 100 percent pure chicken meat, with no bones or skin. The mechanically deboned chicken is high in protein and relatively low in fat. The minced chicken resembles finely ground hamburger and can be refrigerated at least five days. "When people look at it, they're a little surprised Baker said. "But it looks like a hamburg grind, except it's ground finer.

The color Is like hamburg." In addition to chicken burgers, the product can be used in such dishes as chicken chili, chicken stroganoff and sloppy joes, Baker said. HE ACKNOWLEDGED Americans are "big hamburger eaters, regardless of the price and will always be." The chicken meat Baker has used for his new product comes from hens which have finished producing eggs. The supply of Leghorns is about 200 million annually. There Is, however, little demand for them. The breed of scrawny white feathered chickens was developed in the Mediterranean region.

expressed distaste for the personal publicity that surrounded the doctor when his polio breakthrough came and for the fact that some who contributed to the vaccine's success received little credit. Although Salk was considered for the Nobel Prize, the 65-year old scientist never received it. He also has not been elected by his peers to the National Academy of Sciences, as Sabin has. A NOBEL PRIZE was given in 1954 to viro! oglst John F. Enders for growing polio virus in human-tissue cultures, a crucial step in the vaccine research.

Today, Salk is philosophical about honors and prizes. "That's all so long past in my career that It's Just a reflection on the system," he says. But he still has strong opinions on the question of killed-virus versus live virus vaccines. "It's a matter of principle," he insists. "It is not a Salk versus Sabin controversy, a competition between two people.

The question of live- versus killed-virus immunization began to i i.